Ni Xiao-Chun, Yi Yong, Fu Yi-Peng, Cai Xiao-Yan, Liu Gao, Huang Jin-Long, Gan Wei, Xu Jie, Qiu Shuang-Jian
Shanghai Ninth People's Hospital, General Surgery, Shanghai, People's Republic of China.
Liver Cancer Institute, Hepatic Surgery, Shanghai, People's Republic of China.
Onco Targets Ther. 2020 Dec 16;13:12867-12880. doi: 10.2147/OTT.S279997. eCollection 2020.
To further clarify the association between abnormal levels of serum lipid components as the main features of dyslipidaemia and hepatocellular carcinoma, which remains unclear.
We examined the serum level of lipids and apolipoproteins pattern in 471 patients undergoing curative resection for HCC, 193 patients with chronic liver disease, and 104 patients with benign liver diseases. We performed uni- and multivariate analyses to evaluate the predictive roles of lipids and apolipoproteins for recurrence and survival of HCC in a training cohort of 242 patients and then validated in a cohort of 229 patients.
The majority circulating lipid and apolipoprotein levels such as ApoA1, HDL, and LDL in chronic liver disease and HCC were slightly significantly decreased as compared to those in benign lesion. But no significant differential expression patterns of lipids and apolipoproteins were observed between chronic liver hepatitis and HCC. Multivariable analysis identified ApoA1 as a key parameter related to recurrence and survival in both training and validation cohorts. Moreover, we further demonstrated that low ApoA1 was an independent prognostic factor of poor early recurrence in two cohorts.
Although the alterations of circulating lipids and apolipoproteins were observed in HCC, none of lipids or apolipoproteins could serve as a diagnostic marker. Serum ApoA1 merits consideration as a novel prognostic marker for patients with HCC undergoing surgery since it predicts early recurrence and survival, especially for early stage patients and may improve the prognostic stratification of patients for clinical management and promote HCC clinic outcomes.
血脂异常的主要特征为血清脂质成分水平异常,目前其与肝细胞癌之间的关联尚不清楚,本研究旨在进一步阐明二者之间的关系。
我们检测了471例接受肝癌根治性切除术的患者、193例慢性肝病患者和104例良性肝病患者的血脂水平和载脂蛋白谱。我们进行了单因素和多因素分析,以评估脂质和载脂蛋白对242例患者训练队列中肝癌复发和生存的预测作用,然后在229例患者队列中进行验证。
与良性病变患者相比,慢性肝病和肝癌患者中大多数循环脂质和载脂蛋白水平,如载脂蛋白A1、高密度脂蛋白和低密度脂蛋白,均有轻微显著下降。但慢性肝炎和肝癌之间未观察到脂质和载脂蛋白的显著差异表达模式。多变量分析确定载脂蛋白A1是训练队列和验证队列中与复发和生存相关的关键参数。此外,我们进一步证明低载脂蛋白A1是两个队列中早期复发不良的独立预后因素。
虽然在肝癌患者中观察到循环脂质和载脂蛋白的改变,但脂质或载脂蛋白均不能作为诊断标志物。血清载脂蛋白A1值得作为接受手术的肝癌患者的一种新的预后标志物加以考虑,因为它可预测早期复发和生存,尤其是对早期患者,并且可能改善患者的预后分层以用于临床管理并促进肝癌临床结局。